Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2025-12-26 @ 2:12 AM
Study NCT ID:
NCT03715205
Status:
COMPLETED
Last Update Posted:
2025-08-29
First Post:
2018-10-19
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-01-31
Start Date Type:
ACTUAL
Primary Completion Date:
2024-08-21
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-08-21
Completion Date Type:
ACTUAL
First Submit Date:
2018-10-19
First Submit QC Date:
None
Study First Post Date:
2018-10-23
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-08-11
Results First Submit QC Date:
None
Results First Post Date:
2025-08-29
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-11
Last Update Post Date:
2025-08-29
Last Update Post Date Type:
ESTIMATED